Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
1 Year : From Nov 2018 to Nov 2019
By Michael Dabaie
Ionis Pharmaceuticals Inc. (IONS) said Monday its partner Roche (RHHBY) enrolled the first patient in a pivotal study of RG6042 for Huntington's disease.
With the initiation of the study, Ionis said it earned a $35 million milestone payment.
Roche and Ionis are collaborating to develop antisense drugs to treat Huntington's disease. In total, Ionis has generated $135 million in up-front, milestone and license payments and is eligible to receive additional milestone payments as RG6042 progresses in development, as well as royalties.
Huntington's disease is a hereditary neurodegenerative disorder for which there is currently no approved disease-modifying treatment, Ionis said.
Write to Michael Dabaie at email@example.com
(END) Dow Jones Newswires
January 28, 2019 07:53 ET (12:53 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.